PANTHERx® Specialty Pharmacy, THE Rare Disease Specialty Pharmacy®, announced the addition of industry veteran Susan Faust to its executive leadership team as Senior Vice President and Head of Markets. In this role, Faust will be responsible for leading...

PANTHERx® Specialty Pharmacy, THE Rare Disease Specialty Pharmacy®, announced that it has been selected by Insmed Incorporated to distribute ARIKAYCE® (amikacin liposome inhalation suspension), the first and only therapy specifically indicated for the...

PANTHERx® Specialty Pharmacy, THE Rare Disease SP®, announces that is has been named 2018-2019 Specialty Pharmacy of the Year by the National Association of Specialty Pharmacy (NASP). The prestigious award was presented by the NASP President at the sixth...

PANTHERx® Specialty Pharmacy, The Rare Disease Specialty Pharmacy®, is thrilled and proud to announce that it has been named to the 37th Annual Inc. 5000 list, recognizing the fastest-growing private companies in America. PANTHERx® is being recognized...

PANTHERx® Specialty Pharmacy (PANTHERx®), THE Rare Disease Specialty Pharmacy®, announced that it has been selected by Ultragenyx Pharmaceutical, Inc. to distribute Crysvita™ (burosumab-twza), the very first FDA-approved therapy for children and adults...

PANTHERx® Specialty Pharmacy (PANTHERx®), THE Rare Disease Specialty Pharmacy®, announced that it has been selected by Otsuka America Pharmaceutical, Inc. (Otsuka) to distribute JYNARQUE™ (tolvaptan), the only FDA-approved therapy for patients diagnosed...